- Home
- JHX vs ROIV Comparison
JHX vs ROIV Comparison
Compare JHX & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JHX | ROIV |
|---|---|---|
| Founded | 1888 | 2014 |
| Country | Ireland | United Kingdom |
| Employees | N/A | N/A |
| Industry | Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.8B | 14.1B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | JHX | ROIV |
|---|---|---|
| Price | $20.59 | $22.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 8 |
| Target Price | ★ $27.33 | $21.94 |
| AVG Volume (30 Days) | 6.5M | ★ 6.7M |
| Earning Date | 11-17-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.40 | N/A |
| Revenue | ★ $4,116,899,999.00 | $20,329,000.00 |
| Revenue This Year | $24.54 | N/A |
| Revenue Next Year | $15.32 | $376.94 |
| P/E Ratio | $60.94 | ★ N/A |
| Revenue Growth | ★ 4.60 | N/A |
| 52 Week Low | $16.46 | $8.73 |
| 52 Week High | $29.83 | $22.45 |
Technical Indicators
Market Signals| Indicator | JHX | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 61.67 | 68.21 |
| Support Level | $18.77 | $20.14 |
| Resistance Level | $20.72 | $21.48 |
| Average True Range (ATR) | 0.51 | 0.66 |
| MACD | 0.23 | -0.02 |
| Stochastic Oscillator | 94.96 | 87.12 |
Price Performance
Historical ComparisonAbout JHX James Hardie Industries plc (Ireland)
James Hardie is a manufacturer of fiber cement-based building products, selling primarily to the residential construction industry. North America is the primary geography, generating about 80% of group earnings. Here, it is the largest manufacturer of fiber cement, which is mainly used for exterior siding on houses. Following the Azek acquisition in 2025, it also produces wooden composite decking materials, siding trims, and accessories for outdoor areas including stair and deck railing. Businesses in Australia, New Zealand, and Europe, make up the rest of earnings.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.